carfilzomib | 2 Minute Medicine

#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma

byTeddy Guo

April 5, 2023

0

Click to read this study in The Lancet Oncology.

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

byAlice Wangand1 others

July 1, 2021

0

1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone. 2. Improved median ...

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

byKathleen Lau

March 25, 2021

0

$#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma$

#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma

byKathleen Lau

March 19, 2021

0

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

byKathleen Lau

March 12, 2021

0

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

byKathleen Lau

February 19, 2021

0

#VisualAbstract Renal Toxicity Associated with Carfilzomib in Multiple Myeloma Patients

byKathleen Lau

December 3, 2020

0

Tag: carfilzomib

#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma

Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

#VisualAbstract Renal Toxicity Associated with Carfilzomib in Multiple Myeloma Patients

Recent Reports